Behrman Capital Makes Significant Investment in Emmes
Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.
Behrman Capital has a 25-year track record of successfully investing in growing healthcare services companies, adding resources and professional services to help them innovate and expand.
“This is a substantial and exciting milestone in our evolution,” said Dr. Anne Lindblad, president and chief executive officer of Emmes. “The Emmes name will continue, as will our vision, mission, leadership, and focus on advancing human health. We will benefit from Behrman’s investment, expertise and relationships. We believe this investment will allow us to provide employees even greater opportunities as we continue to build and grow.
“Our government work is and will remain core, and we plan to accelerate our efforts on the non-government side,” she added.
According to Grant Behrman, managing partner of Behrman Capital, “Emmes has world class talent and an outstanding reputation in clinical research. It has built an especially strong legacy in the government sector and, in particular, at the National Institutes of Health. Our role is to invest in the company’s future growth, from employee development to expanded offerings to current and prospective clients.”
“We believe Behrman’s investment will speed the development and integration of tools that increase the efficiency of conducting research studies,” noted Dr. Lindblad. “This should have a direct, positive impact to our clients. In addition, Behrman will be a great help in expanding our global presence, sharing market research that can shape new business opportunities, and identifying key hires that would complement our existing team.”
Last year, Emmes was 83rd, up from 95th the previous year, in the Washington Business Journal’s annual ranking of the area’s top private companies. It also was one of only two biotech companies recognized by The Washington Post in its Top Workplaces ranking. The company’s revenues have increased nearly 27% percent over the past two years, from $90 million in 2016 to $114 million in 2018. The company has two offices in Maryland, one in Northern Virginia, one in Canada, and two in India.
About Behrman Capital
Based in New York City and San Francisco, Behrman Capital was founded in 1991 by Grant G. and Darryl G. Behrman. It has raised more than $3 billion since its formation, and healthcare services is one of the firm’s three industry focuses.
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com.